hour
versu
day
attract
altern
leflunomid
applic
organ
transplant
leflunomid
n
prodrug
easili
convert
open
ring
metabolit
almost
vitro
vivo
assay
describ
exhibit
activ
describ
leflunomid
mna
design
structur
similar
leflunomid
insolubl
water
suspend
carboxymethylcellulos
oral
administr
halflif
leflunomid
human
long
day
drug
metabol
predominantli
liver
oral
bioavail
substanti
affect
food
gender
effect
pharmacokinet
observ
phase
studi
leflunomid
analogu
strong
antiprolif
effect
lymphocyt
especi
b
lymphocyt
product
partial
inhibit
leflunomid
kinet
studi
activ
lymphocyt
shown
addit
exogen
uridin
revers
antiprolif
effect
leflunomid
leflunomid
retain
inhibitori
activ
uridin
ad
hour
initi
stimul
inhibit
pyrimidin
synthesi
propos
import
mechan
action
molecularli
confirm
show
direct
leflunomidemedi
inhibit
enzym
dihydroorot
dehydrogenas
lymphocyt
reli
entir
de
novo
pathway
pyrimidin
biosynthesi
use
anoth
socal
pyrimidin
salvag
pathway
dihydroorot
dehydrogenas
inhibit
lead
deplet
nucleotid
precursor
uridin
triphosph
cytidin
triphosph
necessari
synthesi
rna
dna
henc
strongli
suppress
dna
rna
synthesi
although
report
mention
immunosuppress
effect
vivo
overcom
administ
uridin
confirm
model
vivo
mechan
action
leflunomid
may
depend
factor
drug
level
dispos
uridin
pool
immun
activ
pathway
involv
particular
studi
indic
addit
inhibit
dihydroorot
dehydrogenas
leflunomid
mna
may
act
inhibit
tyrosin
kinas
phosphoryl
epiderm
growth
factor
receptor
human
fibroblast
shown
inhibit
brequinar
sodium
leflunomid
initi
develop
antitumor
drug
brequinar
sodium
agricultur
herbicid
leflunomid
explor
immunosuppress
abil
inhibit
enzym
dihydroorot
dehydrogenas
key
enzym
pyrimidin
biosynthesi
addit
shown
exert
immunosuppress
activ
suppress
sever
tyrosin
kinas
immunosuppress
effect
leflunomid
first
shown
model
adjuv
arthriti
graftversushost
diseas
clinic
known
effect
safe
treatment
rheumatoid
arthriti
potenti
leflunomid
immunosuppress
transplant
extens
shown
variou
experiment
studi
long
halflif
sever
day
may
pose
problem
potenti
overimmunosuppress
transplant
patient
analogu
activ
metabolit
leflunomid
acid
trifluoromethylphenylamid
develop
call
malononitrilamid
mna
also
known
mna
trifluoromethyl
phenyl
acid
beststudi
synthet
mna
much
shorter
halflif
leflunomid
leflunomid
also
shown
leflunomid
directli
inhibit
interleukin
il
protein
tyrosin
kinas
activ
associ
activ
cell
complex
higher
concentr
also
inhibit
tyrosin
phosphoryl
janu
kinas
protein
tyrosin
kinas
initi
signal
receptor
studi
attempt
design
inhibitor
antiapoptot
tyrosin
kinas
bruton
tyrosin
kinas
btk
leflunomid
analogu
shown
exhibit
strong
inhibitori
activ
btk
key
factor
cellindepend
antibodi
format
effect
leflunomid
may
explain
high
potenc
suppress
cellindepend
igm
xenoantibodi
format
see
later
hypothesi
leflunomid
may
exhibit
one
mechan
action
vivo
illustr
mice
uridin
restor
prolifer
igm
product
lipopolysaccharidestimul
b
cell
wherea
suppress
igg
product
revers
phenomenon
correl
dosedepend
manner
tyrosin
phosphoryl
protein
known
involv
signal
transduct
pathway
doubl
vivo
mechan
action
confirm
rat
xenogen
reactiv
counteract
administr
uridin
wherea
alloreact
effect
leflunomid
mna
describ
inhibit
variou
macrophag
function
particular
product
oxygen
radic
inhibit
igemedi
hypersensit
respons
express
receptor
type
tumor
necrosi
factor
tnf
mediat
nuclear
factor
activ
equival
stronger
immunosuppress
activ
leflunomid
vitro
vivo
immunosuppress
effect
synergist
calcineurin
inhibitor
mycophenol
mofetil
leflunomid
shown
possess
antivir
effect
inhibit
viral
replic
member
herpesviru
famili
prevent
tegument
acquisit
viral
nucleocapsid
late
stage
virion
assembl
leflunomid
effect
multidrugresist
cytomegaloviru
vitro
although
vitro
activ
modest
select
index
low
rat
model
heterotop
heart
transplant
anticytomegaloviru
effect
leflunomid
confirm
unaffect
uridin
administr
success
treatment
leflunomid
polyomaviru
type
bk
nephropathi
cytomegaloviru
renal
transplant
patient
report
leflunomid
vasculoprotect
effect
independ
inhibit
dihydroorot
dehydrogenas
also
inhibit
matur
dendrit
cell
vitro
prevent
upregul
activ
marker
product
phenomenon
revers
exogen
uridin
variou
transplant
experi
rat
leflunomid
shown
least
equal
potenc
cyclosporin
abl
synerg
cyclosporin
induc
toler
specif
characterist
leflunomidemedi
immunosuppress
rat
abil
interrupt
ongo
acut
reject
efficaci
prevent
treat
chronic
vascular
reject
one
attract
characterist
leflunomid
mna
strong
capac
delay
xenograft
reject
induc
partial
xenograft
toler
capac
may
relat
strong
suppress
effect
leflunomid
cellindepend
xenoantibodi
format
abil
induc
natur
killer
cell
nonrespons
modul
xenoantigen
express
monotherapi
rat
combin
microemulsifi
cyclosporin
dog
tacrolimu
nonhuman
primat
reduc
chronic
allograft
nephropathi
significantli
prolong
renal
allograft
surviv
leflunomid
use
studi
involv
transplant
patient
yet
suboptim
pharmacokinet
profil
doubleblind
random
multicent
trial
rheumatoid
arthriti
patient
efficaci
leflunomid
found
superior
placebo
similar
sulfasalazin
overal
well
toler
phase
ii
multicent
studi
perform
involv
renal
transplant
patient
combin
tacrolimu
corticosteroid
patient
receiv
experienc
fewer
acut
reject
effect
graft
surviv
week
reduct
acut
reject
episod
pronounc
subgroup
target
level
obtain
second
week
mean
total
lowdens
lipoprotein
cholesterol
level
lower
group
placebo
group
although
rat
toler
leflunomid
well
longterm
administr
dog
develop
anemia
gastrointestin
ulcer
frequent
side
effect
arthriti
patient
receiv
longterm
leflunomid
treatment
report
diarrhea
nausea
alopecia
rash
lead
dropout
rate
arthriti
trial
previous
mention
phase
ii
studi
involv
dosedepend
increas
side
effect
includ
anemia
hypokalemia
symptomat
myocardi
ischemia
esophag
leflunomid
newer
design
analogu
mna
warrant
care
investig
transplant
patient
especi
effect
antibodi
format
chronic
vascular
lesion
synerg
cyclosporin
tacrolimu
may
valuabl
brequinar
sodium
origin
develop
antitumor
drug
extens
data
safeti
issu
regard
use
brequinar
antineoplast
agent
interest
drug
immunosuppress
control
graft
reject
stimulatedc
brequinar
substitut
carboxyl
acid
acid
sodium
salt
watersolubl
compound
readili
absorb
oral
administr
peak
concentr
obtain
approxim
hour
oral
administr
halflif
human
report
hour
two
third
breakdown
product
excret
fece
one
third
excret
urin
brequinar
inhibit
mix
lymphocyt
reaction
dosedepend
manner
concentr
requir
produc
inhibit
speci
depend
vari
human
monkey
human
substanti
interindividu
variat
inhibit
valu
previous
mention
first
mechan
action
brequinar
inhibit
enzym
dihydroorot
dehydrogenas
evidenc
fact
vitro
vivo
effect
brequinar
revers
administr
uridin
mode
action
explain
antiprolif
effect
brequinar
abil
reduc
mrna
level
interferon
ifn
lymphocyt
b
lymphocyt
affect
explain
effect
brequinar
cellmedi
humor
immun
immunosuppress
effect
brequinar
unaffect
uridin
supplement
howev
suggest
anoth
mechan
action
may
involv
respect
shown
brequinar
inhibit
tyrosin
phosphoryl
murin
lymphocyt
shown
brequinarmedi
control
lymphadenopathi
autoantibodi
product
mrllprlpr
mice
depend
partial
inhibit
pyrimidin
nucleotid
synthesi
rather
associ
vivo
inhibit
protein
tyrosin
phosphoryl
rat
brequinar
treatment
three
time
weekli
day
recipi
associ
perman
kidney
liver
allograft
surviv
prolong
heart
allograft
surviv
difficult
achiev
requir
longer
period
treatment
surviv
time
small
bowel
allograft
hamster
xenograft
rat
recipi
shown
prolong
equal
brequinar
treatment
differ
mechan
action
brequinar
cyclosporin
led
expect
potenti
synergist
action
would
allow
signific
dose
reduct
brequinar
fewer
side
effect
brequinar
shown
activ
b
lymphocyt
wherea
princip
target
cell
cyclosporin
cell
although
synergist
effect
brequinar
cyclosporin
document
variou
experiment
model
combin
complic
enhanc
toxic
two
compound
result
drug
accumul
xenograft
reject
humor
immun
respons
crucial
shown
success
inhibit
combin
treatment
brequinar
cyclosporin
similarli
brequinar
treatment
transplant
allogen
heart
previous
sensit
recipi
significantli
delay
graft
reject
associ
suppress
antibodi
respons
donor
tissu
follow
approv
phase
studi
brequinar
test
patient
receiv
kidney
transplant
patient
receiv
standard
cyclosporin
steroid
therapi
addit
brequinar
initi
within
hour
transplant
given
altern
day
aim
plasma
level
less
mgml
first
seri
patient
evid
indic
number
reject
episod
significantli
reduc
initi
posit
result
confirm
studi
howev
enthusiasm
drug
temper
narrow
rang
therapeut
effect
risk
thrombocytopenia
high
dose
rat
combin
brequinar
cyclosporin
shown
lead
enhanc
toxic
compound
result
drug
accumul
human
common
side
effect
high
dose
thrombocytopenia
mucos
although
characterist
brequinar
suggest
would
attract
immunosuppress
suboptim
pharmacolog
profil
jeopard
use
transplant
patient
futur
use
drug
transplant
would
requir
develop
analogu
exhibit
shorter
halflif
less
toxic
spergualin
watersolubl
peptid
isol
cultur
filtrat
bacillu
latersporu
explor
new
anticanc
antibiot
substanc
analogu
subsequ
becam
wide
known
promis
new
immunosuppress
spergualin
synthet
dehydroxyl
produc
poor
oral
bioavail
must
deliv
parenter
drug
rapidli
elimin
primarili
kidney
precis
mode
action
unknown
specif
bind
hsp
heatshock
protein
believ
princip
effect
inhibit
activ
transcript
factor
antigenpres
cell
monocyt
premis
may
explain
inhibit
monocyt
macrophag
function
antigen
present
major
histocompat
class
ii
upregul
releas
superoxid
product
cellspecif
function
concanavalin
blastogenesi
mix
lymphocyt
reaction
respons
product
poorli
affect
affect
contrast
b
lymphocyt
matur
antibodi
product
sensit
basi
characterist
consid
particular
immunomodulatori
agent
uniqu
mechan
action
anim
experi
seem
effect
use
prevent
reject
treatment
initi
sever
day
transplant
howev
drug
found
much
effect
observ
suggest
may
use
treatment
reject
crise
suggest
confirm
dog
treatment
reject
subsequ
becam
major
indic
clinic
use
see
later
effect
monocyt
macrophag
b
lymphocyt
seem
promis
xenotransplant
illustr
fact
effect
stringent
xenogen
transplant
model
primari
nonfunct
islet
xenograft
induct
xenogen
chimer
pigtobaboon
combin
clinic
transplant
experi
obtain
mostli
patient
reject
sever
clinic
trial
evalu
effect
treatment
kidney
allograft
reject
overal
result
indic
cours
monotherapi
revers
acut
reject
reject
alreadi
chronic
phase
cours
highdos
methylprednisolon
ad
result
improv
respect
overal
treatment
recurr
reject
effect
treatment
first
episod
reject
effect
antibodi
format
also
explor
conjunct
cyclosporin
prednisolon
antilymphocyt
globulin
capac
inhibit
secondari
antibodi
product
aboincompat
hlapresensit
kidney
transplant
recipi
pig
islet
xenograft
recipi
safe
effect
aboincompat
preform
antibodyposit
kidney
transplant
prophylact
therapeut
regimen
acut
reject
two
three
patient
small
amount
urinari
porcin
cpeptid
detect
sever
week
indic
surviv
xenogen
fetal
porcin
islet
recent
kirk
colleagu
found
combin
alemtuzumab
fail
induc
toler
small
seri
live
donor
kidney
transplant
recipi
experi
limit
draw
firm
conclus
clinic
studi
involv
common
side
effect
subject
complaint
facial
numb
gastric
discomfort
symptom
disappear
soon
infus
interrupt
bone
marrow
suppress
common
seriou
side
effect
respond
effect
treatment
recombin
granulocyt
colonystimul
factor
analogu
develop
allow
oral
administr
major
clinic
indic
limit
treatment
reject
crise
may
altern
steroid
antilymphocyt
agent
fact
remain
effect
recurr
administr
promis
futur
xenotransplant
becom
realiti
may
becom
import
especi
islet
xenotransplant
effect
macrophag
b
lymphocyt
may
essenti
tackl
difficult
problem
primari
graft
nonfunct
synthet
structur
analogu
myriocin
metabolit
ascomycet
isaria
sinclairii
fungu
veget
wasp
molecular
weight
dalton
ethyl
hydrochlorid
chemic
structur
differ
cyclosporin
current
immunosuppress
given
daili
oral
gavag
mark
antireject
properti
mice
rat
dog
monkey
mgkg
prolong
surviv
skin
allograft
highli
allogen
rodent
model
datolew
rat
combin
short
cours
peritranspl
oral
mgkg
day
prolong
cardiac
allograft
surviv
effici
posttranspl
treatment
mgkg
cardiac
liver
allograft
surviv
prolong
acitolew
rat
model
either
induct
mainten
treatment
even
delay
administr
interrupt
ongo
allograft
reject
suggest
role
rescu
agent
block
reject
also
graftversushost
diseas
rat
intestin
transplant
peritranspl
posttranspl
mgkgday
also
profound
immunosuppress
properti
kidney
transplant
monkey
dog
liver
transplant
dog
small
larg
anim
model
provid
evid
act
synergi
calcineurin
inhibitor
cyclosporin
benefit
result
pharmacokinet
interact
induct
cours
act
synergi
posttranspl
prolong
cardiac
allograft
surviv
rat
similar
phenomenon
observ
use
transplant
combin
cyclosporin
rat
skin
heart
allograft
show
synergist
effect
cyclosporin
heart
liver
transplant
acitolew
rat
model
show
synergi
cyclosporin
kidney
transplant
dog
mgkgday
monkey
mgkgday
final
mgkg
synerg
cyclosporin
dog
liver
transplant
synergi
rapamycin
also
observ
cardiac
transplant
rat
contrast
cyclosporin
poor
inhibitor
cell
function
vitro
particular
influenc
antigeninduc
product
lack
vitro
immunosuppress
activ
contrast
mark
antireject
properti
seen
vivo
rat
receiv
one
oral
dose
mgkg
show
rapid
profound
decreas
peripher
lymphocyt
count
count
remain
significantli
depress
return
pretreat
level
within
day
fluorescenceactiv
cell
sorter
analysi
indic
specif
reduct
cell
unchang
cell
ratio
first
suggest
lymphocytopenia
result
apoptot
lymphocyt
death
vitro
exposur
high
concentr
induc
chromatin
condens
typic
dna
fragment
format
apoptot
bodi
apoptosi
administr
also
document
vivo
caus
intragraft
apoptot
lymphocyt
death
anim
ongo
liver
allograft
reject
second
mechan
action
alter
lymphocyt
traffick
administr
mgkg
mgkg
mice
label
b
cell
cell
immedi
leav
peripher
blood
migrat
peripher
lymph
node
mesenter
lymph
node
peyer
patch
label
cell
return
peripher
blood
withdraw
drug
undergo
apoptot
death
migrat
equival
cell
cell
cell
b
cell
alter
cell
traffick
accompani
reduct
lymphocyt
infiltr
graft
organ
phenomenon
would
contribut
antireject
properti
drug
lymphocyt
treat
ex
vivo
reintroduc
vivo
similarli
migrat
peripher
lymphoid
tissu
indic
act
directli
lymphocyt
effect
abolish
previou
exposur
pertussi
toxin
suggest
modul
g
proteincoupl
chemokin
receptor
cell
surfac
lymphocyt
addit
process
acceler
home
complet
block
vivo
coadministr
monoclon
antibodi
suggest
directli
affect
home
receptor
suggest
regulatori
cell
differ
affect
compar
effector
cell
regulatori
cell
express
lower
level
sphingosin
receptor
show
reduc
respons
vitro
regulatori
cell
possess
increas
suppress
activ
antigenspecif
prolifer
assay
presenc
increas
express
certain
intercellular
adhes
molecul
human
umbil
vein
endotheli
cell
vitro
alter
cell
traffick
may
result
direct
action
lymphocyt
also
effect
endotheli
cell
receptor
also
present
murin
dendrit
cell
administr
dendrit
cell
lymph
node
spleen
reduc
express
downregul
transendotheli
migrat
diminish
murin
model
cardiac
transplant
alloantigenspecif
effectormemori
cell
sequestr
region
lymphoid
tissu
decreas
cell
infiltr
allograft
observ
treatment
delay
administr
attenu
progress
vasculopathi
interstiti
fibrosi
suggest
interrupt
traffick
activ
effectormemori
cell
pulmonari
cardiac
neurolog
toxic
report
anim
expos
high
dose
parent
compound
myriocin
induc
sever
digest
toxic
therapeut
dose
seem
well
toler
dose
mgkg
caus
clinic
toxic
rat
studi
dog
indic
dose
mgkg
equal
well
toler
day
mgkg
toxic
observ
cardiac
transplant
rat
receiv
posttranspl
singl
dose
mgkg
lethal
howev
given
transplant
rat
liver
recipi
monkey
treat
mgkg
show
specif
side
effect
typic
side
effect
calcineurin
inhibitorsnephrotox
neurotox
diabetogenicityhav
observ
stabl
renal
transplant
patient
maintain
cyclosporin
toler
well
one
oral
dose
mg
particular
pulmonari
toxic
note
although
clinic
asymptomat
episod
bradycardia
observ
one
episod
headach
led
drug
withdraw
similar
effect
anim
singl
dose
caus
lymphocytopenia
dose
depend
intens
durat
affect
cell
cell
memori
cell
naiv
cell
b
cell
equal
monocyt
granulocyt
count
remain
unchang
dose
mg
caus
rapidli
revers
decreas
lymphocyt
count
nadir
hour
higher
dose
result
sustain
profound
lymphocytopenia
maxim
concentr
area
curv
proport
dose
indic
pharmacokinet
profil
linear
volum
distribut
larger
blood
volum
indic
widespread
tissu
penetr
undergo
hepat
metabol
long
halflif
hour
indic
extend
pharmacolog
action
bioavail
adequ
intersubject
variabl
low
phase
ii
studi
de
novo
renal
transplant
mg
found
effect
mmf
combin
cyclosporin
prevent
acut
reject
renal
transplant
well
toler
associ
side
effect
commonli
observ
immunosuppress
therapi
promis
new
type
immunosuppress
agent
immunomodul
uniqu
structur
mechan
action
receptor
modul
mark
antireject
effect
modifi
lymphocyt
traffick
alter
express
function
adhes
molecul
provok
migrat
lymphocyt
peripher
blood
secondari
lymphoid
tissu
reduct
allograft
lymphocyt
infiltr
peripher
lymphocytopenia
effect
dose
depend
revers
discontinu
drug
also
may
caus
lymphocyt
apoptosi
probabl
higher
dose
amelior
prevent
reject
use
induct
mainten
therapi
ongo
acut
reject
interrupt
posttranspl
act
synergi
calcineurin
inhibitor
cyclosporin
rapamycin
ongo
experiment
work
suggest
also
may
protect
ischemiareperfus
injuri
addit
role
clinic
organ
transplant
may
prove
use
treatment
inflammatoryautoimmun
condit
first
studi
rat
involv
benzyloxyphenylthio
ethyl
hydrochlorid
similar
molecular
structur
publish
alon
combin
lowdos
cyclosporin
mycophenol
acid
prolong
skin
heart
allograft
surviv
attenu
bradycardia
mechan
action
oh
new
synthet
structur
analogu
promis
immunomodul
effect
autoimmun
transplant
immunolog
detect
receptor
oh
vitamin
receptor
almost
cell
immun
system
especi
antigenpres
cell
macrophag
dendrit
cell
activ
lymphocyt
led
investig
potenti
role
oh
immunomodul
addit
activ
macrophag
dendrit
cell
abl
synthes
secret
oh
regul
fashion
macrophag
activ
secret
classic
macrophag
product
preced
transcript
vitamin
enzym
respons
final
ratelimit
step
synthesi
oh
consequ
product
oh
time
synthesi
secret
compat
suppress
neg
feedback
signal
oh
stimul
differenti
monocyt
toward
good
phagocytosi
kill
bacteria
suppress
antigenpres
capac
essenti
latter
suppress
surfac
express
hla
class
ii
molecul
classic
adhes
molecul
necessari
full
cell
stimul
inhibit
hla
class
ii
costimulatori
molecul
express
also
observ
surfac
dendrit
cell
vitro
vivo
treatment
oh
analogu
dendrit
cell
antigenpres
cell
par
excel
deviat
toward
immatur
tolerogen
phenotyp
vitro
vivo
capac
induc
develop
regulatori
cell
crucial
cytokin
secret
antigenpres
cell
monocyt
dendrit
cell
recruit
activ
cell
directli
influenc
oh
key
cytokin
determin
direct
immun
system
activ
inhibit
oh
analogu
therebi
oh
directli
interfer
heart
immun
cascad
shift
immun
reaction
toward
helper
type
profil
addit
express
dendrit
cell
immunosuppress
oppos
effect
increas
treatment
oh
analogu
although
major
immunomodulatori
effect
oh
mediat
action
antigenpres
cell
cell
also
direct
target
oh
cytokin
directli
inhibit
oh
wherea
cytokin
stimul
molecular
pathway
oh
modul
express
gene
immun
system
vari
wide
next
classic
interact
vitamin
receptorspecif
bind
site
promot
region
target
gene
vitamin
drespons
element
inhibit
oh
also
interfer
pathway
transcript
regul
oh
mediat
inhibit
due
impair
complex
format
subsequ
associ
bind
site
within
promot
inhibit
monocyt
dendrit
cell
oh
target
pathway
activ
bind
bind
site
within
promot
subunit
repress
oh
fact
oh
analogu
influenc
immun
system
immunomodul
induct
immun
shift
regul
cell
make
product
appeal
clinic
use
especi
treatment
prevent
autoimmun
diseas
anim
model
autoimmun
diabet
nod
mous
upregul
regul
cell
shift
away
toward
could
observ
oh
treat
mice
local
pancrea
peripher
immun
system
restor
defect
sensit
apoptosi
characterist
nod
lymphocyt
observ
result
better
elimin
autoreact
effector
cell
increas
sensit
apoptosi
describ
differ
apoptosisinduc
signal
mechan
may
explain
earli
shortterm
oh
treatment
clinic
onset
autoimmun
lead
longterm
protect
restor
selftoler
arrest
progress
autoimmun
diabet
nod
mice
treat
analogu
oh
shown
associ
enhanc
frequenc
regulatori
cell
pancreat
lymph
node
clear
addit
even
synergist
effect
observ
oh
analogu
classic
immunosuppress
cyclosporin
sirolimu
mycophenol
mofetil
vitro
differ
vivo
autoimmun
diseas
model
autoimmun
diabet
experiment
autoimmun
encephalomyel
oh
analogu
investig
variou
transplant
model
pancreat
islet
allotransplant
xenotransplant
mice
allogen
heart
skin
transplant
mice
allogen
aorta
bone
marrow
heart
kidney
liver
transplant
rat
overal
conclus
drawn
studi
monotherapi
oh
analogu
provok
modest
prolong
graft
function
surpris
view
weak
intrins
effect
oh
analogu
cell
conjunct
immunosuppress
strong
synergist
effect
often
observ
howev
addit
view
effect
antigen
present
direct
immun
system
direct
oh
may
help
induc
toler
major
concern
remain
howev
side
effect
oh
calcium
bone
metabol
use
oh
analogu
maintain
amplifi
immunomodulatori
effect
combin
reduc
effect
calcium
bone
alreadi
partial
conquer
problem
addit
use
calciumlow
method
limit
nutrient
calcium
intak
bone
resorpt
inhibitor
bisphosphon
aid
bypass
neg
side
effect
hypercalcemia
excess
bone
resorpt
facilit
step
toward
clinic
applic
oh
analogu
potent
immunomodulatori
properti
cyclophosphamid
bi
amino
oxazaphosphorin
first
synthes
arnold
colleagu
cellular
uptak
extens
metabol
drug
first
transform
hydroxyl
intermedi
cytochrom
system
hydroxyl
intermedi
undergo
breakdown
form
activ
compound
phosphoramid
mustard
acrolein
reaction
phosphoramid
mustard
dna
result
cell
death
high
dose
cyclophosphamid
effect
immunosuppress
agent
experiment
allograft
model
perhap
specif
b
lymphocyt
basi
shortterm
followup
small
seri
patient
starzl
cowork
suggest
cyclophosphamid
might
substitut
azathioprin
good
result
complic
achiev
use
tripl
therapi
antilymphocyt
globulin
cyclophosphamid
prednisolon
previou
experi
cyclophosphamid
small
seri
good
probabl
high
dose
administ
cyclophosphamid
use
combin
azathioprin
prednisolon
treatment
chronic
steroidresist
reject
although
benefit
achiev
seriou
complic
note
two
small
control
trial
shown
cyclophosphamid
intermitt
bolus
first
week
transplant
benefici
complic
cyclophosphamid
sever
leukopenia
thrombocytopenia
hemorrhag
cystiti
nausea
vomit
complic
found
rare
howev
studi
patient
given
lowdos
cyclophosphamid
replac
azathioprin
liver
dysfunct
evid
inadequ
immunosuppress
possibl
immunosuppress
effect
cyclophosphamid
never
adequ
test
dosag
suffici
low
avoid
complic
possibl
suggest
report
yadav
colleagu
show
live
relat
transplant
recipi
given
cyclophosphamid
instead
azathioprin
hepat
dysfunct
high
cost
unavail
azathioprin
complic
attribut
directli
cyclophosphamid
minim
author
conclud
cyclophosphamid
safe
effect
altern
azathioprin
standard
indic
cyclophosphamid
transplant
today
desensit
highli
sensit
recipi
renal
transplant
protocol
involv
repeat
plasmapheresi
combin
cyclophosphamid
either
without
continu
steroid
kidney
transplant
perform
bredinin
nucleosid
analogu
structur
similar
ribavirin
isol
cultur
media
soil
fungu
eupenicillium
brefeldianum
antibiot
agent
activ
candida
albican
bredinin
exert
immunosuppress
function
select
inhibit
enzym
inosin
monophosph
dehydrogenas
guanosin
monophosph
synthetas
requir
gener
guanosin
monophosph
inosin
monophosph
de
novo
pathway
previous
bredinin
use
mainli
japan
infrequ
use
elsewher
canin
model
renal
transplant
bredinin
prolong
graft
surviv
human
compar
azathioprin
bredinin
show
equal
potent
immunosuppress
activ
fewer
advers
effect
similar
structur
ribavirin
bredinin
also
exhibit
vitro
antivir
activ
cytomegaloviru
respiratori
syncyti
viru
measl
hepat
c
viru
coronaviru
parainfluenza
influenza
viru
conclus
experi
bredinin
today
limit
result
show
safe
effect
immunosuppress
human
kidney
transplant
phase
iii
trial
way
franc
germani
unit
kingdom
renal
transplant
patient
tyrosin
kinas
essenti
signal
transduct
common
chain
cytokin
receptor
nucleu
express
restrict
immun
cell
featur
make
attract
target
new
immunosuppress
defici
result
sever
combin
immunodefici
syndrom
bone
marrow
transplant
cur
sever
combin
immunodefici
syndrom
patient
conclud
essenti
function
system
organ
sever
inhibitor
developedtyrphostin
dimethoxyquinazolin
compound
mannich
base
studi
acut
lymphoblast
leukemia
cell
conclud
tyrphostin
select
inhibitor
bystand
inhibitori
activ
cell
line
show
specif
inhibitori
activ
rat
combin
tyrphostin
cyclosporin
result
prolong
heart
allograft
antibiot
undecylprodigioisin
famili
inhibitor
rat
model
heart
transplant
prolong
allograft
surviv
show
synerg
cyclosporin
origin
design
antileukem
drug
prevent
acut
graftversushost
diseas
preserv
graftversusleukemia
effect
prevent
onset
diabet
nod
mice
platelet
function
disturb
effect
independ
inhibit
rais
issu
select
drug
potent
inhibitori
potenc
nm
select
inhibitor
date
rodent
nonhuman
primat
exert
strong
suppress
immun
reaction
prolong
heart
kidney
allograft
surviv
monotherapi
significantli
delay
onset
reject
kidney
allograft
nonhuman
primat
significantli
reduc
cell
product
express
inhibit
cellular
alloimmun
respons
vitro
administr
vivo
result
reduct
natur
killer
cell
cell
number
wherea
effector
memori
cell
unaffect
common
side
effect
anemia
due
inhibit
signal
erythropoietin
receptor
anoth
possibl
detriment
result
interfer
signal
relat
fact
toler
induct
essenti
depend
pathway
mannich
base
preferenti
inhibit
prolong
kidney
allograft
surviv
induc
transplant
toler
rat
without
toxic
effect
conclus
specif
inhibitor
show
great
promis
new
effect
immunosuppress
side
effect
clinic
studi
autoimmun
diseas
organ
transplant
progress
cladribin
adenosin
deaminaseresist
analogu
deoxyadenosin
use
treatment
leukemia
lymphoma
mani
studi
explor
immunosuppress
capac
cladribin
vitro
cladribin
inhibit
b
cell
cell
prolifer
vivo
cladribin
monotherapi
shown
prolong
skin
allograft
surviv
mice
combin
cyclosporin
prolong
liver
heart
allograft
surviv
rat
effect
cyclosporin
monotherapi
small
bowel
allograft
clinic
trial
publish
date
farnesyltransferas
inhibitor
develop
anticanc
compound
inhibit
ra
guanosin
triphosphatas
inhibit
lectininduc
prolifer
antigenpres
cellinduc
cell
prolifer
compound
also
inhibit
lymphocyt
cytokin
product
promot
apoptosi
lectinactiv
lymphocyt
fr
immunosuppress
agent
isol
cultur
pseudomona
fluorescen
inhibit
activ
transcript
activ
act
predominantli
antigenpres
cell
fr
show
synergi
tacrolimu
vitro
vivo
murin
model
skin
transplant
compar
optim
dose
tacrolimu
alon
combin
fr
tacrolimu
prolong
graft
surviv
sever
decad
total
lymphoid
irradi
tli
use
treat
hodgkin
diseas
possibl
appli
tli
immunosuppress
regimen
rather
anticanc
treatment
discov
investig
stanford
univers
studi
involv
patient
hodgkin
diseas
show
cellular
immun
function
sever
impair
wherea
secondari
hematolog
tumor
rare
infect
commonli
observ
tli
local
herp
zoster
infect
tli
deliv
two
port
first
socal
mantl
port
includ
lymph
node
neck
axilla
mediastinum
port
call
invert
encompass
aortic
iliac
pelvic
lymph
node
spleen
usual
total
dose
gy
gy
rad
administ
daili
fraction
gy
much
current
avail
experiment
evid
immunolog
mechan
underli
tliinduc
toler
point
import
suppressor
cell
strober
group
identifi
posttli
suppressor
cell
hosttyp
natur
killer
cell
protect
effect
tli
graftversushost
diseas
abrog
mice
inactiv
gene
hosttyp
natur
killer
cell
produc
stimul
donortyp
cell
also
produc
definit
evid
function
import
activ
suppressor
cell
provid
demonstr
could
prevent
graftversushost
diseas
vivo
posttli
attenu
effector
lymphocyt
reactiv
propos
equal
respons
observ
immunosuppress
state
tli
intrins
cell
defect
depend
irradi
thymu
extrathym
tissu
tli
anerg
cell
shown
incap
prolifer
even
presenc
exogen
studi
tli
shown
lead
thymic
clonal
delet
donorreact
hostreact
lymphocyt
tlitreat
mice
also
exhibit
decreas
antidonor
cytotox
cell
precursor
frequenc
final
strober
group
show
lymphocyt
recov
soon
tli
wherea
lymphocyt
remain
defici
sever
month
show
defect
also
prevent
thymic
shield
irradi
domin
tli
confirm
group
rodent
larg
anim
tlitreat
balbc
mice
receiv
fulli
allogen
bone
marrow
skin
graft
first
day
tli
becam
stabl
hematopoiet
chimera
without
sign
graftversushost
diseas
develop
perman
donorspecif
toler
preserv
antithirdparti
reactiv
toler
induct
critic
depend
width
irradi
field
time
transplant
tli
total
dose
tli
absenc
presensit
follow
promis
result
rodent
transplant
experi
use
tli
perform
dog
although
bone
marrow
chimer
could
easili
induc
toler
either
heart
kidney
allograft
obtain
suggest
tliinduc
bone
marrow
chimer
creat
toler
toward
organspecif
antigen
combin
tli
lowdos
cyclosporin
found
effect
clinic
safe
rat
tli
postop
antithymocyt
globulin
induc
perman
specif
transplant
toler
toward
heart
allograft
transplant
dog
encourag
result
led
similar
trial
clinic
kidney
transplant
discuss
later
myburgh
associ
appli
modifi
tli
regimen
baboon
low
dosag
wide
field
exposur
show
toler
achiev
larger
anim
without
concomit
bone
marrow
transplant
princip
disadvantag
clinic
applic
tli
complet
regimen
fraction
daili
irradi
need
administ
complet
suffici
close
moment
transplant
find
suitabl
donor
organ
within
restrict
time
frame
problemat
investig
explor
possibl
use
tli
transplant
mous
rat
heart
allograft
model
posttransplant
tli
significantli
prolong
graft
surviv
combin
monoclon
antibodi
infus
donortyp
dendrit
cell
precursor
pretransplant
tli
combin
cyclosporin
cyclosporin
pretranspl
splenectomi
cyclosporin
monoclon
antibodi
deoxyspergualin
result
significantli
longer
graft
surviv
rate
combin
previous
use
also
heart
heartlung
transplant
experi
xenogen
nonhuman
primat
speci
preoper
tli
administ
combin
cyclosporin
antithymocyt
globulin
cyclosporin
splenectomi
cyclosporin
methylprednisolon
effici
treatment
regimen
pretransplant
tli
combin
cyclosporin
methotrex
pig
heartintobaboon
model
result
graft
surviv
time
week
regimen
inhibit
xenoreact
natur
antibodi
product
xenoreact
macrophag
pig
isletintorat
xenograft
model
tli
combin
deoxyspergualin
extrem
effect
even
discord
lambintopig
model
tli
synerg
cyclosporin
azathioprin
provok
increas
mean
xenograft
surviv
time
first
clinic
kidney
transplant
use
tli
perform
univers
minnesota
patient
previous
reject
renal
allograft
similar
result
increas
graft
surviv
compar
histor
control
data
achiev
patient
popul
use
cyclosporin
eas
administr
investig
conclud
cyclosporin
prefer
tli
control
trial
perform
univers
leuven
belgium
patient
endstag
diabet
nephropathi
receiv
cadav
kidney
allograft
investig
effect
pretransplant
tli
daili
fraction
gy
follow
onceweekli
tli
dose
suitabl
donor
found
follow
lowdos
posttransplant
prednison
mainten
treatment
longterm
followup
reveal
reject
episod
frequent
patient
graft
surviv
significantli
inferior
tlitreat
group
excess
mortal
tlitreat
patient
due
sepsi
result
highdos
steroid
therapi
need
treat
reject
crise
clinic
experi
confirm
anim
data
also
show
tli
alon
insuffici
provok
longterm
graft
surviv
toler
extra
manipul
need
studi
stanford
univers
patient
receiv
first
patient
second
cadav
renal
allograft
use
tli
antithymocyt
globulin
actuari
graft
surviv
year
ten
patient
never
reject
crisi
despit
overal
poor
hla
match
donor
recipi
leuven
studi
phenotyp
suppressorcytotox
lymphocyt
reveal
posttli
suppressorcytotox
cell
cytotox
compar
control
subject
expans
within
suppressorcytotox
subpopul
observ
tli
entir
due
increas
suppressor
cell
followup
studi
specif
antidonor
mix
lymphocyt
cultur
hyporespons
nonrespons
shown
patient
immunosuppress
drug
could
withdrawn
evalu
larger
group
patient
treat
protocol
center
show
graft
surviv
less
cyclosporinetr
patient
synerg
tli
cyclosporin
studi
comparison
convent
immunosuppress
regimen
alg
prednisolon
azathioprin
patient
rome
univers
patient
treat
convent
immunosuppress
retain
function
graft
wherea
tlitreat
patient
function
graft
among
never
reject
crisi
use
widefield
tli
regimen
shown
effect
baboon
studi
human
univers
johannesburg
actuari
graft
surviv
significantli
better
unsensit
patient
year
seven
patient
die
transplantrel
caus
five
function
graft
fact
two
patient
immunosuppress
drug
could
stop
sever
year
other
lowdos
mainten
immunosuppress
cyclosporin
mgkg
prednisolon
mgday
oral
use
without
reject
crisi
seem
confirm
result
obtain
baboon
model
anim
becam
specif
toler
posttranspl
tli
combin
monoclon
antibodi
antithymocyt
globulin
donorspecif
blood
transfus
seem
effect
rat
heart
allograft
model
basi
result
efficaci
tli
evalu
heart
transplant
patient
therapyresist
earli
vascular
reject
tli
result
signific
reduct
reject
recurr
effect
maintain
least
year
favor
result
confirm
sever
group
also
tlitreat
patient
develop
less
coronari
atherosclerosi
match
control
despit
multipl
reject
episod
tli
treatment
progress
bronchiol
obliteran
syndrom
lung
transplant
retrospect
evalu
patient
recent
studi
tli
significantli
reduc
rate
declin
forc
expiratori
volum
second
well
toler
associ
sever
complic
although
tli
shown
safe
immunosuppress
regimen
also
becom
evid
ineffici
induc
toler
larg
anim
model
human
cumbersom
administ
consequ
tli
abandon
clinic
practic
except
treatment
therapyresist
reject
heart
heartlung
transplant
view
increas
interest
xenotransplant
potenti
tli
interfer
xenogen
reactiv
must
explor
fact
tli
may
concomitantli
influenc
celldepend
cellindepend
immun
may
import
immun
arm
known
equal
import
reject
xenograft
extracorpor
photopheresi
techniqu
leukocyt
remov
patient
leukapheresi
expos
ultraviolet
light
develop
immunoregulatori
treatment
erythroderm
cutan
cell
lymphoma
subsequ
procedur
shown
safe
altern
treatment
variou
human
immun
autoimmun
diseas
rat
monkey
regimen
shown
result
extend
skin
allograft
cardiac
allograft
xenograft
surviv
differ
mechan
shown
contribut
immunomodulatori
effect
photopheresi
includ
select
inhibit
effector
cell
induct
high
rate
apoptosi
increas
capac
phagocytos
apoptot
cell
result
induct
anticlonotyp
immun
respons
shift
toward
immun
activ
clinic
transplant
photopheresi
appli
therapeut
prophylact
option
appli
treatment
recurr
resist
acut
reject
renal
transplant
patient
number
patient
includ
studi
limit
prospect
random
trial
need
safeti
efficaci
photopheresi
prevent
acut
reject
cardiac
allograft
evalu
primari
cardiac
allograft
recipi
randomli
assign
standard
tripledrug
immunosuppress
therapi
cyclosporin
azathioprin
prednison
alon
conjunct
photopheresi
session
perform
first
month
transplant
month
followup
photopheresistr
patient
develop
significantli
fewer
reject
signific
differ
rate
type
infect
although
signific
effect
graft
surviv
rate
month
studi
indic
photopheresi
may
effect
new
immunosuppress
regimen
transplant
recipi
patient
refractori
bronchiol
obliteran
lung
transplant
photopheresi
result
stabil
graft
function
patient
result
histolog
revers
reject
splenectomi
splenectomi
recipi
transplant
first
propos
starzl
colleagu
mean
improv
graft
surviv
although
splenectomi
standard
procedur
patient
develop
hypersplen
azathioprineassoci
leukopenia
evid
role
splenectomi
enhanc
graft
surviv
controversi
larg
prospect
random
trial
minneapoli
show
splenectomi
improv
graft
surviv
significantli
longer
term
followup
show
loss
benefici
effect
increas
infectionrel
mortal
sever
singlecent
studi
shown
alarm
risk
sepsi
death
nullifi
earli
benefit
splenectomi
graft
surviv
multicent
analysi
south
eastern
organ
procur
foundat
confirm
modest
improv
graft
surviv
splenectomi
relentless
increas
patient
mortal
splenectomi
may
place
prepar
recipi
receiv
aboincompat
graft
practic
like
becom
wide
use
live
relat
donor
transplant
aboincompat
otherwis
suitabl
donor
avail
donor
alexandr
associ
report
seri
aboincompat
live
donor
transplant
recipi
prepar
plasmapheresi
donorspecif
platelet
transfus
splenectomi
although
author
believ
need
plasmapheresi
donorspecif
platelet
transfus
reevalu
splenectomi
thought
import
recipi
splenectomi
lost
graft
acut
vascular
reject
contrast
undergo
splenectomi
ishikawa
colleagu
japan
report
smallscal
success
experi
postsplenectomi
aboincompat
live
donor
kidney
transplant
antigenspecif
immunoadsorpt
rituximab
treatment
develop
recent
howev
altern
plasmapheresi
splenectomi
set
aboincompat
kidney
transplant
plasmapheresi
plasmapheresi
appli
three
set
first
treatment
steroidresist
acut
reject
morpholog
predominantli
vascular
consid
antibodymedi
rather
cellmedi
although
initi
report
suggest
benefici
effect
control
trial
unconvinc
nojima
colleagu
report
success
treatment
antibodymedi
acut
renal
allograft
reject
combin
plasmapheresi
second
set
prepar
recipi
aboincompat
live
donor
kidney
refer
earlier
although
brynger
cowork
report
success
aboincompat
graft
without
prior
plasmapheresi
recipi
third
set
plasmapheresi
use
attempt
reduc
titer
broad
reactiv
hla
antibodi
highli
sensit
candid
transplant
dialysi
patient
combin
cyclophosphamid
therapi
prevent
reappear
antibodi
encourag
earli
result
approach
report
although
associ
consider
morbid
immunoadsorpt
appli
altern
plasmapheresi
found
equal
effici
method
studi
approach
highli
sensit
candid
transplant
recipi
continu
particular
search
drug
select
prevent
synthesi
antibodi
perhap
may
less
toxic
cyclophosphamid
